Onderneming Neuropathix, Inc.
Aandelen
NPTX
US64132Q1094
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 6
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dean Petkanas
CEO | Chief Executive Officer | 60 | 25-07-18 |
Mark Corrao
DFI | Director of Finance/CFO | 67 | 25-07-18 |
William Kinney
CTO | Chief Tech/Sci/R&D Officer | 66 | 25-07-18 |
Robert Malasek
BRD | Director/Board Member | 55 | 20-06-17 |
Mark McDonnell
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Malasek
BRD | Director/Board Member | 55 | 20-06-17 |
Timothy Scott
BRD | Director/Board Member | 71 | 25-07-18 |
Dean Petkanas
CEO | Chief Executive Officer | 60 | 25-07-18 |
Blake Schroeder
BRD | Director/Board Member | 48 | 25-07-18 |
Thomas Kikis
FOU | Founder | 46 | 25-07-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 93 810 559 | 71 724 607 ( 76,46 %) | 0 | 76,46 % |
Bedrijfsgegevens
Neuropathix, Inc.
Pennsylvania Biotechnology Center 3805 Old Easton Road
18902, Doylestown
+
http://www.neuropathix.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,26% | 104 mld. | |
+1,41% | 97,42 mld. | |
+0,79% | 22,2 mld. | |
-17,84% | 21,23 mld. | |
-11,11% | 18,33 mld. | |
-42,83% | 16,35 mld. | |
-17,63% | 15,06 mld. | |
+4,55% | 13,98 mld. | |
+32,11% | 11,66 mld. |